Drugs for Combined Therapy: Experimental Studies on the Antileprosy Activity of Ethionamide and Prothionamide, and a General Review

M. J. COLSTON
St George’s Hospital Medical School, London SW17 0RE, U.K.
G. A. ELLARD AND PATRICIA T. GAMMON
MRC Unit for Laboratory Studies of Tuberculosis
Royal Postgraduate Medical School,
Ducane Road, London W12 0HS, U.K.

The activity of ethionamide and prothionamide against Mycobacterium leprae has been evaluated using the mouse footpad model. The minimum effective doses of both drugs were found to be approximately 0.01%, and their minimal inhibitory concentrations were estimated to be about 0.05 µg/ml. Both compounds were found to be bactericidal against M. leprae at dietary concentrations of 0.1%. These findings indicate the importance of studies to evaluate the potential role of ethionamide and prothionamide in clinical practice. The available experimental evidence concerning the relative antileprosy activities of drugs that might be used in the combined treatment of lepromatous patients is reviewed.

Introduction
The importance of finding new antileprosy drugs for use in combined treatment to combat the growing problem posed by the widespread emergence of dapsone-resistant strains of Mycobacterium leprae was discussed in the previous paper (Colston et al., 1978b). In the current paper we report the determination of the minimum effective doses (MEDs) of ethionamide and prothionamide against several strains of M. leprae using the mouse footpad technique. Estimations of the minimal inhibitory concentrations (MICs) of these 2 drugs against M. leprae are also described, together with studies to assess the extent of their bactericidal activity. Finally we review current knowledge concerning the relative activities of the presently available antileprosy drugs.

The antituberculosis drug ethionamide (α-ethyl thioisonicotinamide) has been used to a limited extent in the treatment of leprosy, but has not gained
widespread acceptance because of the relatively high incidence of gastric intolerance when it is given at dose levels normally used for the treatment of tuberculosis (500–750 mg per day). The most extensive study of ethionamide in the treatment of leprosy was made by Rollier and Rollier (1972), who treated 102 lepromatous patients with an initial dosage of 1 g per day. However, because of side effects, they subsequently reduced the daily dosage to 500 mg for adults and 250 mg for children. They concluded that the lower dosage of ethionamide was well tolerated, and after 4 years treatment most of the patients had a Bacterial Index of zero. The acceptability of lower doses of ethionamide accords with the excellent tolerance of the drug encountered when it was given at a dosage of 250 mg per day in the earlier study of Floch, Rist and Jacobi (1966).

Prothionamide (α-propyl thioisonicotinamide), the propyl analogue of ethionamide, has largely replaced ethionamide in the treatment of tuberculosis, since its activity against \( M. \) \( \text{tuberculosis} \) is equal or slightly superior to that of ethionamide (Grumbach et al., 1956; Rist, 1960; Noufflard-Guy-Loé and Berteaux, 1962), and because patients have generally been found to tolerate prothionamide slightly better than ethionamide (Bruet, Chevallier and Névot, 1962; Molina et al., 1964; Chambatte et al., 1965; Martin-Lalande et al., 1966; British Tuberculosis Association, 1968; Co-operative Study Unit on Chemotherapy of Tuberculosis of the National Sanatoria in Japan, 1968; Fox et al., 1969). Freerksen (1975) has advocated the use of prothionamide in combination treatment, but it is difficult to assess from published reports the precise dosage of prothionamide employed by his collaborators.

In the mouse footpad, ethionamide has been found to be inactive against \( M. \) \( \text{leprae} \) when fed at 0.001% in the diet, bacteriostatic at 0.01%, and bactericidal at 0.1% or 0.2% (Shepard, 1969a,b, 1976). Prothionamide has not been tested previously for antileprosy activity in the mouse footpad.

**Methods**

**DETERMINATION OF THE MINIMUM EFFECTIVE DOSES**

The minimum effective doses (MEDs) of ethionamide and prothionamide were determined using the methods described in the accompanying paper (Colston et al., 1978b). Three strains of \( M. \) \( \text{leprae} \) were used (SBL 16220, SBL 15337 and TG), and the 2 drugs were administered at dietary concentrations of 0.001%, 0.003%, 0.01% and 0.03% commencing on the day of inoculation and continuing throughout the experiment.

**ASSESSMENT OF BACTERICIDAL ACTIVITY**

Ethionamide and prothionamide were administered to mice infected with \( M. \) \( \text{leprae} \) strain TG at dietary concentrations of 0.03%, 0.1% and 0.2%, starting on the day of inoculation and continuing for 60 days. Monitoring of bacillary growth and assessment of bactericidal activity were carried out as described previously (Colston et al., 1978b).
DETERMINATION OF MOUSE SERUM CONCENTRATIONS OF ETHIONAMIDE AND PROTHIONAMIDE

Because of the insensitivity of currently available ultraviolet methods for determining ethionamide and prothionamide in the serum (see Jenner and Ellard, 1978), and the small amounts of serum obtainable from mice, a radiochemical method was devised for measuring mouse serum ethionamide and prothionamide concentrations using the same basic approach as that described for the determination of thiacetazone (Colston et al., 1978b). A novel gas–liquid chromatographic procedure, capable of measuring down to about 0.2 \( \mu g \) ethionamide or prothionamide in 1 ml serum, was also devised and used to analyse sera from mice fed with the highest dietary concentrations of the 2 drugs (0.2%).

(a) Radiochemical method

Batches of \(^{14}\)C-labelled ethionamide or prothionamide, with specific activities ranging from about 0.05–1 mCi/mM were prepared for feeding to mice at dietary concentrations of 0.2%–0.01%, respectively, by mixing methanolic solutions containing 1 mg/ml of ethionamide or prothionamide labelled in the thiocarbamyl group, and unlabelled ("cold") drug, and evaporating to dryness under reduced pressure.

Groups of 10 mice were fed for 24 h on diet containing 0.01%, 0.03%, 0.1% and 0.2% \(^{14}\)C-labelled ethionamide or prothionamide, and the concentrations of the drugs determined in pooled serum. In order to ascertain whether prolonged administration might induce the metabolism of these drugs, other groups of mice were fed 0.1% unlabelled ethionamide or prothionamide for 14 days prior to feeding 0.1% of the \(^{14}\)C-labelled formulations in the diet for 24 h and determining the serum concentrations of the 2 drugs.

A 1 ml aliquot of serum from mice fed for 24 h on diet containing \(^{14}\)C-labelled ethionamide or prothionamide was pipetted into a small centrifuge tube together with 0.1 ml of a methanolic solution containing 1 mg/ml "cold" ethionamide or prothionamide to act as a "marker" to estimate the recovery of the drugs in the separation system, and ethionamide/prothionamide extracted by shaking with 2 ml ether. This solvent was chosen to minimize any potential contribution from sulphoxide metabolites of the drugs to the assay (Kane, 1962). After centrifugation the upper organic phase was decanted using a Pasteur pipette and then extracted by shaking with 0.5 ml 0.1 \( N \) hydrochloric acid. The lower acid extract was then transferred to another centrifuge tube, 0.1 ml M dipotassium hydrogen phosphate added and the ethionamide/prothionamide extracted by shaking with 0.1 ml chloroform.

The chloroform extract was dried onto a silica gel thin layer chromatography plate (Merck) and then developed with acetone/methanol (1:1 v/v) for 50 min. After drying and examining under ultraviolet light, the u.v.-absorbing spot was scraped off and eluted by shaking with 2 ml methanol in a small centrifuge tube. This was centrifuged and the overall recovery of ethionamide/prothionamide in the combined separation procedure was determined by measuring the extinction of the methanol extract at its absorption maximum (approximately 290 nm). A 1.5 ml aliquot of the methanol extract was then dried down in a scintillation vial, 5 ml of 0.6% butyl-PBD in toluene added and counted in a scintillation counter. The concentration of ethionamide/prothionamide in the original mouse serum could then be estimated by calculating the ratio of the extract's radioactivity ([counts per min] absorbance) and comparing it with the ratio for standards prepared from the appropriate \(^{14}\)C-labelled thioamide preparation in blank serum, taken through the same procedure.

(b) Gas–liquid chromatographic method

A 1 ml aliquot of serum was pipetted into a small centrifuge tube together with 0.1 ml of a methanolic solution containing 10 \( \mu g \)/ml ethionamide/prothionamide (prothionamide for the determination of ethionamide; ethionamide for the determination of prothionamide) to act as internal standard and extracted by shaking with 4 ml ether. After centrifugation, the ether extract was extracted with 1 ml 0.1 \( N \) hydrochloric acid. The acid extract was then transferred to
another centrifuge tube and the thioamides extracted into 1 ml chloroform after the addition of 0.2 ml M dipotassium hydrogen phosphate. The chloroform extract was transferred to a small tapered centrifuge tube, evaporated to dryness at 50°C under a stream of nitrogen and the residue redissolved in 20 μl chloroform, from which aliquots of 1 μl were injected onto the gas–liquid chromatography column.

Chromatography was carried out at 160°C on a coiled glass column (7 ft long × 2 mm i.d.) silanized with dimethyl dichlorosilane and packed with 3% OV-225 on Gas Chrom Q (100–120 mesh) using a Pye 104 instrument equipped with a flame-ionization detector. The injector and detector were maintained at 170° and 250°, respectively, and the flow-rates were carrier gas (nitrogen) 25, air 600 and hydrogen 50 ml/min. Under these conditions the approximate retention times of ethionamide and prothionamide were 1.6 and 2.2 min, respectively, and a linear relationship was obtained between the ratios of the peak heights of test drug to internal standard for initial ethionamide/prothionamide concentrations of 0.2 to 5 μg/ml.

Results

The results of the studies to determine the minimum effective doses of ethionamide and prothionamide are summarized in Table 1. The growth of the 3 strains of *M. leprae* was partially suppressed by feeding 0.003% ethionamide in the diet, and totally suppressed by 0.01%, confirming the results previously obtained by Shepard (1969a). The multiplication of strains SBL 15337 and TG was completely prevented by feeding 0.01% prothionamide, although 0.03% was required to entirely suppress the growth of strain SBL 16220. It was therefore concluded that the MEDs of both drugs were approximately 0.01%.

### TABLE 1

*Estimation of the minimum effective dose (MED) of ethionamide and prothionamide against *M. leprae*

<table>
<thead>
<tr>
<th><em>M. leprae</em> strain</th>
<th>Percentage drug in the diet</th>
<th>MED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td></td>
</tr>
</tbody>
</table>

**Ethionamide**

<table>
<thead>
<tr>
<th></th>
<th>5/6*†</th>
<th>0/6</th>
<th>0/6</th>
<th>0.01%</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBL 16220</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBL 15337</td>
<td>4/6</td>
<td>0/6</td>
<td>0/6</td>
<td>0.01%</td>
</tr>
<tr>
<td>TG</td>
<td>5/6</td>
<td>0/6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Prothionamide**

<table>
<thead>
<tr>
<th></th>
<th>6/6</th>
<th>2/6</th>
<th>0/6</th>
<th>0.03%</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBL 16220</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBL 15337</td>
<td>6/6</td>
<td>0/6</td>
<td>0/6</td>
<td>0.01%</td>
</tr>
<tr>
<td>TG</td>
<td>6/6</td>
<td>4/6</td>
<td>0/6</td>
<td>0.01%</td>
</tr>
</tbody>
</table>

* Not tested.
† Number of footpads positive/number of footpads harvested.

The concentrations of ethionamide and prothionamide in the serum of mice fed various dosages of the 2 drugs determined using the radiochemical method are illustrated in Fig. 1. The results obtained when mice were fed 0.2% of the drugs in the diet were confirmed using the gas–liquid chromatographic method. Serum concentrations of both drugs were approximately proportional to the percentages fed in the diet, and, since there was no significant difference between the results obtained for ethionamide and prothionamide, a single regression line was plotted. The serum concentrations of ethionamide and pro-
Fig. 1. Serum concentrations of ethionamide (●) and prothionamide (■) of mice fed for 24 h on diet containing graded doses of \(^{14}\text{C}\)-labelled drug. Open symbols (○, □) represent the values obtained in mice fed for 14 days with unlabelled drug, followed by labelled drug for 24 h.

Thionamide in mice that had been fed with the drugs for 14 days were no lower than those that had only been fed on drug-containing diets for 24 h, indicating that the metabolism of neither drug had been induced.

The minimal inhibitory concentrations (MICs) of both ethionamide and prothionamide against \(M. \text{leprae}\), defined as the serum concentrations present in mice fed with the MEDs of the 2 drugs (0.01%), were estimated from the data illustrated in Fig. 1 as being about 0.05 \(\mu\text{g}/\text{ml}\). Thus, as had been previously demonstrated with \(M. \text{tuberculosis}\), both drugs appear to have rather similar antitymocobacterial activity.

The results of the kinetic experiment to assess the potential bactericidal activity of the 2 drugs are summarized in Table 2. Neither ethionamide nor prothionamide showed any bactericidal activity when administered for 60 days at 0.03% as indicated by excess growth delays of only 16 days. However, when the dietary concentration was increased to 0.1%, multiplication of bacilli could not be detected for periods of up to 442 days \textit{post inoculum} when the final harvest was made. The excess growth delay, calculated by drawing a line through the final point parallel to the growth curve for the untreated controls, was 215 days for ethionamide and 225 days for prothionamide. The excess growth delay engendered by feeding 0.2% ethionamide for 60 days was 209 days, while in the single mouse fed on 0.2% prothionamide and sacrificed at day 442 after inoculation, there was no evidence of multiplication of \(M. \text{leprae}\).
TABLE 2
Assessment of antibacterial activity by the kinetic technique: the effect of feeding of graded doses of ethionamide and prothionamide in the diet on the growth of M. leprae in mouse footpads

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose*</th>
<th>Growth delay (days)</th>
<th>Excess growth delay†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethionamide</td>
<td>0.03%</td>
<td>76</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>0.1%</td>
<td>275</td>
<td>215†</td>
</tr>
<tr>
<td></td>
<td>0.2%</td>
<td>269</td>
<td>209†</td>
</tr>
<tr>
<td>Prothionamide</td>
<td>0.03%</td>
<td>75</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>0.1%</td>
<td>285</td>
<td>225†</td>
</tr>
<tr>
<td></td>
<td>0.2%</td>
<td>&gt;332</td>
<td>&gt;272</td>
</tr>
</tbody>
</table>

* Drug administered for 60 days, from day 0.
† Growth delay less period of drug administration.
‡ Estimate based on 1 positive footpad count.

These results indicate that feeding mice with 0.1% or 0.2% ethionamide or prothionamide resulted in significant killing of M. leprae, confirming the findings previously reported by Shepard for ethionamide (Shepard, 1969a, b, 1976). The similarity in the bactericidal activities displayed by ethionamide and prothionamide is also in accord with the results obtained using the more rigorous proportional bactericidal test method (Colston, Hilson and Banerjee, 1978). The bactericidal activity of ethionamide against M. leprae parallels that previously demonstrated against M. tuberculosis both in vitro and in vivo in the mouse (Dickinson and Mitchison, 1966; Rist et al., 1958).

Discussion

ANTILEPROSY ACTIVITY OF ETHIONAMIDE AND PROTHIONAMIDE

The results obtained in this investigation indicate that these 2 drugs deserve serious consideration as candidates for use in the combined treatment of lepromatous leprosy. The minimal inhibitory concentrations of ethionamide and prothionamide against M. leprae determined in this study using the mouse footpad model were about 0.05 µg/ml, or about a tenth of the MICs originally reported against M. tuberculosis using conventional in vitro techniques (Grumbach et al., 1956; Rist, 1960; Noufflard-Guy-Loë and Berteaux, 1962). It would however be unwise to conclude that M. leprae is necessarily much more sensitive than M. tuberculosis to inhibition by the thioamides, since it is possible that the sulphoxide metabolites of the 2 drugs that are formed in man and in the mouse (Kane, 1962; Johnson, Kane and Kibby, 1967; Rossi and Rübsammen, 1977) and have significant antituberculosis activity (Libermann, Rist and Grumbach, 1963; J. Peters and T. Welch, pers. comm., 1978) might also contribute to their antileprosy activity in vivo.

Peak serum concentrations of ethionamide and prothionamide are approximately proportional to dose, with concentrations of about 3 µg/ml being achieved after giving 500 mg of either drug (Riddell, 1960; Gray, Hamilton
and Eidus, 1962; Hughes, Smith and Kane, 1962; D. F. Muggleton, pers. comm., 1965; Jenner and Ellard, 1978). This suggests that, at this dose, peak serum concentrations of the drugs would exceed their MICs against *M. leprae* by a factor of approximately 60-fold. Thereafter serum concentrations fall with a half-life of about 2 h and by 24 h are of the same order as the MIC against *M. leprae* (Jenner and Ellard, 1978). Since significant bactericidal activity against *M. leprae* was demonstrated when ethionamide or prothionamide were fed to mice at 0.1%, and since such dietary concentrations gave rise to serum concentrations of about 0.5 μg/ml, there would seem to be reasonable grounds for hoping that bactericidal activity might be achieved in clinical practice if daily doses of 250–500 mg were given. Furthermore, in view of the established dose dependence of gastric intolerance of the 2 drugs and the appreciably better acceptability of prothionamide, it is likely that daily dosage with 250 mg prothionamide would be excellently tolerated by patients.

**REVIEW OF EXPERIMENTAL EVIDENCE CONCERNING THE RELATIVE ACTIVITIES OF ANTILEPROSY DRUGS**

The experimental data currently available concerning the relative activities of antileprosy drugs are summarized in Table 3. This Table shows the MICs of the drugs against *M. leprae* determined in the mouse footpad system, the ratios of peak serum concentrations to MIC for doses of the drugs that are well tolerated by patients, the durations for which serum concentrations exceed the MIC after such doses and the degree of bactericidal activity assessed using the proportional bactericidal test method (Colston *et al.*, 1978a).

**TABLE 3**

<table>
<thead>
<tr>
<th>Drug</th>
<th>MIC (μg/ml)</th>
<th>Dosage (mg)</th>
<th>Ratio peak serum MIC</th>
<th>Duration for which serum concs exceed MIC (days)</th>
<th>Bactericidal§ activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapsone</td>
<td>0.003</td>
<td>100</td>
<td>500</td>
<td>10</td>
<td>+</td>
</tr>
<tr>
<td>Acedapsone</td>
<td>0.003*</td>
<td>225</td>
<td>15</td>
<td>200</td>
<td>N.T.†</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>0.3</td>
<td>600</td>
<td>30</td>
<td>1</td>
<td>+ + +</td>
</tr>
<tr>
<td>Sulphadimethoxine</td>
<td>20</td>
<td>1500</td>
<td>7</td>
<td>4</td>
<td>N.T.</td>
</tr>
<tr>
<td>Sulphadoxine</td>
<td>35</td>
<td>1500</td>
<td>4</td>
<td>14</td>
<td>N.T.</td>
</tr>
<tr>
<td>Sulphamethoxypyridazine</td>
<td>30</td>
<td>1000</td>
<td>3</td>
<td>3</td>
<td>N.T.</td>
</tr>
<tr>
<td>Thiambutosine</td>
<td>0.5</td>
<td>1500</td>
<td>1</td>
<td>&lt;1</td>
<td>—</td>
</tr>
<tr>
<td>Thiacetazone</td>
<td>0.2</td>
<td>150</td>
<td>8</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Ethionamide‡</td>
<td>0.05</td>
<td>500</td>
<td>60</td>
<td>1</td>
<td>+ +</td>
</tr>
<tr>
<td>Prothionamide‡</td>
<td>0.05</td>
<td>500</td>
<td>60</td>
<td>1</td>
<td>+ +</td>
</tr>
</tbody>
</table>

* Acedapsone is inactive against *M. leprae* but is converted to dapsone – the figures for MIC and peak serum concentration refer to the values for dapsone.
† Not tested.
‡ Results obtained in the present study.
§ –, Purely bacteriostatic; +, ++, +++, relative degrees of bactericidal activity.
A considerable body of evidence is available concerning the activity and pharmacology of the clinically established drugs dapsone, acedapsone (DADD S), and rifampicin. The MIC of dapsone was shown by Peters et al. (1975b) and Levy and Peters (1976) to be about 0.003 µg/ml. Since peak serum levels in man following a dose of 100 mg dapsone are approximately 1.5 µg/ml (Glazko et al., 1968; Peters, Gordon and Karat, 1975; Committee on Experimental Chemotherapy, 1976), the ratio of peak serum concentration to MIC is approximately 500. The serum half-life of dapsone has now been determined in over 200 patients, and found to vary from 13–53 h (Peters et al., 1972; Ellard, Gammon and Harris, 1974; Peters et al., 1974; Gelber and Rees, 1975; Peters et al., 1975a, 1976, 1977). Assuming a representative value of 27 h, one can calculate that a 100 mg dose of dapsone will maintain serum concentrations in excess of the MIC for about 10 days.

Dapsone serum levels in excess of the MIC against M. leprae can be maintained for much longer periods by intramuscular injection of acedapsone (Glazko et al., 1968; Ozawa et al., 1971). A dose of 225 mg acedapsone produces mean peak dapsone plasma concentrations of 0.046 µg/ml, approximately 15 times the MIC, and it may be calculated from the data published by Peters et al., (1977) that plasma concentrations would be maintained above the MIC for about 200 days.

The MIC of rifampicin has been estimated as 0.3 µg/ml (Holmes and Hilson, 1972; Holmes, 1974), and since serum plasma concentrations after dosage with 600 mg are approximately 10 µg/ml, with a half-life of 2–3 h (Furesz et al., 1967; Dans et al., 1970; Acocella et al., 1971, 1972; Jeanes, Jessamine and Eidus, 1972; Boman, 1974; Garnham et al., 1976; Männistö, 1977), the ratio of peak serum concentration to MIC is about 30-fold with inhibitory serum levels being maintained for about 24 h. It should however be noted that more recent estimates of the MED of rifampicin against M. leprae (Waters et al., 1978) are approximately 4 times that originally determined by Holmes and Hilson (1972).

The pertinent data for sulphadimethoxine and sulpha doxine were reported earlier (Ellard, Gammon and Rees, 1970), while the studies from which the values for sulphamethoxypyridazine, thiambutosine and thiacetazone were derived are described in the accompanying paper (Colston et al., 1978b). The relative bactericidal activities shown in the last column of Table 3 were determined using the proportional bactericidal test method (Colston et al., 1978a). The doses of drugs tested in that investigation probably gave serum concentrations in mice that are similar to those achieved in patients under treatment and the relative bactericidal potencies determined experimentally in this way correlated closely with those realized in clinical practice. Corresponding data are not available for clofazimine since its accumulation in reticulo-endothelial cells makes it impossible to estimate its MIC against M. leprae (Banerjee et al., 1974; Levy, 1974), although it is likely that after an extended period of treatment effective concentrations would be maintained for many weeks. Its bactericidal activity assessed using the proportional bactericidal test method was intermediate between that of dapsone and rifampicin (Colston et al., 1978a).
It must be emphasized that the data assembled in Table 3 are very imprecise since the MIC determinations only have the precision with which the MEDs of the drugs have been estimated and because it is usually only practicable to determine MEDs using dietary doses differing by factors of at least 3-fold. Nevertheless the markedly superior ratios of peak serum concentrations to MIC, durations of coverage and estimates of the bactericidal activity displayed by the 2 most clinically potent antileprosy drugs, dapsone and rifampicin, indicate the potential relevance of such properties in attempting to assess the prospects of other medicaments that have yet to be evaluated using properly monitored controlled clinical trials. Thus the substantially lower peak serum/MIC ratios of sulphadimethoxine, sulphadioxide and sulphanmethoxy-pyridazine suggest that the use of these long-acting sulphonamides should be discontinued.

The cross-resistance known to exist with *M. tuberculosis* between the diphenylthioureas, thiacetazone and thioamides (Rist et al., 1959; Bartmann, 1960; Grosset and Benhassine, 1970) indicates that a similar phenomenon might occur for *M. leprae* and that these drugs should therefore be regarded as belonging to the same general class. The evidence summarized in Table 3 and discussed in detail in the previous paper (Colston et al., 1978b) suggests that thiacetazone is a much better candidate for use in combined therapy than thiambutosine. However the results of the present study indicate that ethionamide and prothionamide are even more promising and strongly encourage the initiation of detailed investigations into the clinical and bacteriological efficacy of the 2 drugs.

**Acknowledgements**

This work was supported in part by Grant No. G. 976/766 of the Overseas Development Administration, London, and by the World Health Organization as part of the THELEP programme. We should also like to thank Dr M. Davis of May and Baker and Dr P. Frechet, formerly of Theraplíx, for their help in obtaining samples of $^{14}$C-labelled ethionamide and prothionamide.

**References**


